[go: up one dir, main page]

DK602989D0 - Saponinadjuvans - Google Patents

Saponinadjuvans

Info

Publication number
DK602989D0
DK602989D0 DK602989A DK602989A DK602989D0 DK 602989 D0 DK602989 D0 DK 602989D0 DK 602989 A DK602989 A DK 602989A DK 602989 A DK602989 A DK 602989A DK 602989 D0 DK602989 D0 DK 602989D0
Authority
DK
Denmark
Prior art keywords
saponin adjuvant
saponins
disclosed
substantially pure
admixture
Prior art date
Application number
DK602989A
Other languages
English (en)
Other versions
DK175739B1 (da
DK602989A (da
Inventor
Charlotte A Kensil
Dante J Marciani
Gerald A Beltz
Chung-Ho Hung
Original Assignee
Cambridge Bioscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21996520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK602989(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cambridge Bioscience Corp filed Critical Cambridge Bioscience Corp
Publication of DK602989D0 publication Critical patent/DK602989D0/da
Publication of DK602989A publication Critical patent/DK602989A/da
Application granted granted Critical
Publication of DK175739B1 publication Critical patent/DK175739B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J17/005—Glycosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/256—Polyterpene radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
DK198906029A 1987-05-29 1989-11-29 Saponinadjuvans DK175739B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5522987A 1987-05-29 1987-05-29
US5522987 1987-05-29
PCT/US1988/001842 WO1988009336A1 (en) 1987-05-29 1988-05-31 Saponin adjuvant
US8801842 1988-05-31

Publications (3)

Publication Number Publication Date
DK602989D0 true DK602989D0 (da) 1989-11-29
DK602989A DK602989A (da) 1989-11-29
DK175739B1 DK175739B1 (da) 2005-02-07

Family

ID=21996520

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198906029A DK175739B1 (da) 1987-05-29 1989-11-29 Saponinadjuvans

Country Status (8)

Country Link
EP (1) EP0362279B2 (da)
JP (1) JP2731563B2 (da)
AT (1) ATE116993T1 (da)
AU (1) AU616670B2 (da)
CA (1) CA1331443C (da)
DE (1) DE3852761T3 (da)
DK (1) DK175739B1 (da)
WO (1) WO1988009336A1 (da)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
GB9202933D0 (en) * 1992-02-12 1992-03-25 Smithkline Beecham Biolog Vaccines
US5273965A (en) * 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
US5650398A (en) * 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
NL9301690A (nl) * 1993-08-12 1995-04-18 Seed Capital Investments Verbindingen met adjuvans-activiteit.
AU1077795A (en) * 1993-09-30 1995-04-18 Seed Capital Investments (Sci) B.V. Compounds with adjuvant activity
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5597807A (en) * 1994-08-01 1997-01-28 University Of Saskatchewan Quinoa saponin compositions and methods of use
US5688772A (en) * 1994-08-01 1997-11-18 University Of Saskatchewan Quinoa saponin compositions and methods of use
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
JP2002505665A (ja) * 1997-04-30 2002-02-19 メリュー・オラバックス Ｔｈ１型アジュバントを含有する抗ヘリコバクターワクチン組成物
FR2762787B1 (fr) * 1997-04-30 2000-10-06 Pasteur Merieux Serums Vacc Composition vaccinale anti-helicobacter comprenant un adjuvant de type th1
FR2762788B1 (fr) * 1997-04-30 2000-10-06 Pasteur Merieux Serums Vacc Composition vaccinale anti-helicobacter pour usage par voie systemique sous-diaphragmatique
EP0988053A1 (en) * 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
US6241995B1 (en) 1997-08-08 2001-06-05 University Of Saskatchewan Polygala senega compositions and methods of use
AU5366099A (en) 1998-08-20 2000-03-14 Connaught Laboratories Limited Nucleic acid molecules encoding inclusion membrane protein of (chlamydia)
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
JP2002542203A (ja) 1999-04-19 2002-12-10 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
JP4695763B2 (ja) 1999-05-03 2011-06-08 サノフィ、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
EP1964573B1 (en) 1999-10-22 2014-11-26 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
EP1792995A3 (en) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia secretory locus orf and uses thereof
AU5810201A (en) 2000-05-10 2001-11-20 Aventis Pasteur Immunogenic polypeptides encoded by mage minigenes and uses thereof
KR100831139B1 (ko) 2000-10-18 2008-05-20 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
ATE503493T1 (de) 2001-02-23 2011-04-15 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
CA2502268A1 (en) 2002-10-23 2004-05-06 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
AU2005249212B2 (en) 2004-05-28 2010-05-20 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
US8007806B2 (en) 2005-01-20 2011-08-30 Isconova Ab Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
EP2426141B1 (en) 2005-04-29 2014-10-01 GlaxoSmithKline Biologicals S.A. Method for preventing or treating M tuberculosis infection
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
EP2495327B1 (en) 2006-03-03 2016-09-28 ProMIS Neurosciences Inc. Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
WO2008030154A1 (en) * 2006-09-08 2008-03-13 Hemocue Ab Haemolysing agent
DK2468300T3 (da) 2006-09-26 2018-01-29 Infectious Disease Res Inst Vaccinesammensætning indeholdende syntetisk adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CN103550764A (zh) 2007-03-02 2014-02-05 葛兰素史密丝克莱恩生物有限公司 疫苗组合物及其在刺激免疫反应中的用途
UY31285A1 (es) 2007-08-13 2009-03-31 Vacunas
CA2698157C (en) 2007-09-11 2016-10-11 University Of Guelph Novel polysaccharide immunogens from clostridium difficile
JP2011500730A (ja) 2007-10-26 2011-01-06 ガバニング カウンセル オブ ザ ユニバーシティ オブ トロント Ｔｉｍ−３を用いた治療および診断方法
EP2062594A1 (en) 2007-11-21 2009-05-27 Wyeth Farma, S.A. Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
LT2222710T (lt) 2007-12-24 2016-12-12 Id Biomedical Corporation Of Quebec Rekombinantiniai rsv antigenai
CA2826508C (en) 2008-05-23 2016-07-19 The Regents Of The University Of Michigan Nanoemulsion vaccines
WO2010036938A2 (en) 2008-09-26 2010-04-01 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
SG173194A1 (en) 2009-02-17 2011-09-29 Glaxosmithkline Biolog Sa Inactivated dengue virus vaccine with aluminium-free adjuvant
TWI494125B (zh) 2009-06-05 2015-08-01 Infectious Disease Res Inst 合成的葡萄吡喃糖基脂質佐劑
CN102596243B (zh) 2009-06-16 2015-10-21 密执安大学评议会 纳米乳剂疫苗
MX2012000035A (es) 2009-06-24 2012-02-28 Id Biomedical Corp Quebec Antigenos de virus de sincicio respiratorio recombinantes.
MX2012000036A (es) 2009-06-24 2012-02-28 Glaxosmithkline Biolog Sa Vacuna.
AR077757A1 (es) 2009-07-15 2011-09-21 Novartis Ag Composiciones de proteinas de fusion del virus sincicial respiratorio (rsv) y metodos para su preparacion
US20110110980A1 (en) 2009-09-02 2011-05-12 Wyeth Llc Heterlogous prime-boost immunization regimen
PL2475384T3 (pl) * 2009-09-10 2017-02-28 Merial, Inc. Nowe formulacje szczepionek obejmujące adiuwanty zawierające saponiny
WO2011034950A1 (en) 2009-09-16 2011-03-24 Vaxart, Inc. Immunization strategy to prevent h1n1 infection
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
CA2805741C (en) 2010-07-23 2019-08-13 Karin Bengtsson Loevgren Composition including an iscom matrix and ectodomains
WO2012041669A1 (en) 2010-09-27 2012-04-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
MA34802B1 (fr) 2010-10-15 2014-01-02 Glaxosmithkline Biolog Sa Nouvel antigène
PH12013501204A1 (en) 2010-12-14 2013-07-29 Glaxosmithkline Biologicals Sa Mycobacterium antigenic composition
MD4177C1 (ro) * 2011-01-14 2013-02-28 Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова Metodă de vaccinare contra hepatitei virale B a persoanelor imunocompromise
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
SG194083A1 (en) 2011-04-08 2013-11-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
LT2707385T (lt) 2011-05-13 2017-12-11 Glaxosmithkline Biologicals Sa Iš anksto sulieti rsv f antigenai
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
PE20141547A1 (es) 2011-09-16 2014-10-25 Ucb Pharma Sa Anticuerpos neutralizantes frente a las exotoxinas principales tcda y tcdb de clostridium difficile
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
LT2782598T (lt) 2011-11-23 2020-07-27 In3Bio Ltd. Rekombinantiniai baltymai ir jų terapinis panaudojimas
CA3131037A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
WO2013119856A1 (en) 2012-02-07 2013-08-15 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
JP6619648B2 (ja) 2012-05-16 2019-12-11 イミューン デザイン コーポレイション Ｈｓｖ−２のためのワクチン
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
SG11201500573RA (en) 2012-08-06 2015-02-27 Glaxosmithkline Biolog Sa Method for eliciting in infants an immune response against rsv and b. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
US10232035B2 (en) 2012-09-14 2019-03-19 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes virus and use thereof in vaccines
UY34506A (es) 2012-12-10 2014-06-30 Fernando Amaury Ferreira Chiesa Adyuvante de vacunación, preparación y vacunas que lo contienen
JP6703475B2 (ja) 2013-03-13 2020-06-03 アメリカ合衆国 融合前ｒｓｖｆタンパク質およびそれらの使用
KR102427429B1 (ko) 2013-03-15 2022-08-01 인3바이오 리미티드 자기조립형 합성 단백질
UY35418A (es) 2013-03-15 2014-10-31 Glaxosmithkline Biolog Sa Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
AR095962A1 (es) 2013-04-01 2015-11-25 Moreinx Ab Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos
SG11201508092YA (en) 2013-04-18 2015-10-29 Immune Design Corp Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
KR20160040290A (ko) 2013-08-05 2016-04-12 글락소스미스클라인 바이오로지칼즈 에스.에이. 조합 면역원성 조성물
WO2015063611A2 (en) 2013-11-01 2015-05-07 University Of Oslo Albumin variants and uses thereof
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
MX2016008640A (es) 2013-12-31 2016-10-07 Infectious Disease Res Inst Formulaciones de vacuna de vial unico.
WO2015127278A1 (en) 2014-02-20 2015-08-27 Vaxart, Inc. Formulations for small intestinal delivery
CA2951430A1 (en) 2014-06-13 2015-12-17 Glaxosmithkline Biologicals Sa Immunogenic combinations
WO2015192216A1 (en) 2014-06-20 2015-12-23 University Of Saskatchewan Exotoxin/thermolysin compositions and methods and uses for treating or preventing laminitis
TW201623329A (zh) 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
CN106715458A (zh) 2014-07-18 2017-05-24 华盛顿大学 癌症疫苗组合物及其使用方法
US11083788B2 (en) 2014-10-10 2021-08-10 The Regents Of The University Of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
US10813993B2 (en) 2015-03-03 2020-10-27 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Display platform from bacterial spore coat proteins
WO2016141320A2 (en) 2015-03-05 2016-09-09 Northwestern University Non-neuroinvasive viruses and uses thereof
KR102773575B1 (ko) 2015-06-12 2025-02-27 박사르트, 인크. Rsv 및 노로바이러스 항원들의 소장 내의 전달을 위한 제형들
AU2016315478B2 (en) 2015-09-03 2023-07-13 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
EP3138579A1 (en) 2015-09-05 2017-03-08 Biomay Ag Fusion protein for use in the treatment of a hepatitis b virus infection
EP3374383A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia AMYLOID BETA EPITOPES AND ANTIBODIES
WO2017079831A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
CN108350052A (zh) 2015-11-09 2018-07-31 英属哥伦比亚大学 淀粉样蛋白β中间区域中的表位及其构象选择性抗体
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
EP3430039A1 (en) 2016-03-14 2019-01-23 Universitetet I Oslo Engineered immunoglobulins with altered fcrn binding
WO2017201390A1 (en) 2016-05-19 2017-11-23 The Regents Of The University Of Michigan Novel adjuvant compositions
US11780924B2 (en) 2016-06-21 2023-10-10 University Of Oslo HLA binding vaccine moieties and uses thereof
CA3031135A1 (en) 2016-07-18 2018-01-25 The University Of British Columbia Antibodies to amyloid beta
CN109863169A (zh) 2016-08-23 2019-06-07 葛兰素史密丝克莱恩生物有限公司 具有连接至不变链(cd74)的短片段的抗原的融合肽
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
EP3295956A1 (en) 2016-09-20 2018-03-21 Biomay Ag Polypeptide construct comprising fragments of allergens
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
JP7136777B2 (ja) 2016-12-07 2022-09-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規プロセス
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
EP3554538A2 (en) 2016-12-16 2019-10-23 Institute for Research in Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
US20200254083A1 (en) 2017-06-16 2020-08-13 Glaxosmithkline Biologicals Sa Method of treatment
IL300235A (en) 2017-07-18 2023-03-01 In3Bio Ltd Synthetic proteins and their therapeutic uses
CN111148509A (zh) 2017-07-24 2020-05-12 诺瓦瓦克斯股份有限公司 治疗呼吸系统疾病的方法和组合物
EP3678698A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
US12005112B2 (en) 2017-09-07 2024-06-11 University Of Oslo Vaccine molecules
KR102755593B1 (ko) 2017-09-08 2025-01-20 액세스 투 어드밴스드 헬스 인스티튜트 사포닌을 포함하는 리포솜 제형 및 사용 방법
CA3075207A1 (en) 2017-09-13 2019-03-21 Sanofi Pasteur Human cytomegalovirus immunogenic composition
WO2019090238A1 (en) 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
BR112020010635A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. extração de saponina
MX2020005481A (es) 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Purificacion de saponina.
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
US11278612B2 (en) 2018-03-19 2022-03-22 Novavax, Inc. Multivalent influenza nanoparticle vaccines
EP3569612A1 (en) 2018-05-18 2019-11-20 Biomay Ag Treatment and prevention of house dust mite allergies
JP2021526831A (ja) 2018-06-12 2021-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アデノウイルスポリヌクレオチド及びポリペプチド
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
MX2021001479A (es) 2018-08-07 2021-04-28 Glaxosmithkline Biologicals Sa Novedosos procesos y vacunas.
US11547672B2 (en) 2018-09-14 2023-01-10 Massachusetts Institute Of Technology Nanoparticle vaccine adjuvant and methods of use thereof
US20220184158A1 (en) 2018-12-21 2022-06-16 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
EP3934687A1 (en) 2019-03-05 2022-01-12 GlaxoSmithKline Biologicals S.A. Hepatitis b immunisation regimen and compositions
IT201900007060A1 (it) 2019-05-21 2020-11-21 St Superiore Di Sanita Cellule tumorali ingegnerizzate e loro usi
AU2020283768A1 (en) 2019-05-25 2021-12-23 Access To Advanced Health Institute Composition and method for spray drying an adjuvant vaccine emulsion
BR112021026132A2 (pt) 2019-06-25 2022-02-08 In3Bio Ltd Proteínas sintéticas quiméricas estabilizadas e usos terapêuticos das mesmas
IT201900012540A1 (it) 2019-07-22 2021-01-22 Humanitas Mirasole Spa Inibitori di CHI3L1 e loro usi
WO2021014385A1 (en) 2019-07-24 2021-01-28 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
US20220396797A1 (en) 2019-11-15 2022-12-15 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
US20240115688A1 (en) 2020-12-02 2024-04-11 Glaxosmithkline Biologicals Sa Novel Antigens
EP4313138A1 (en) 2021-03-30 2024-02-07 Viravaxx AG Sars-cov-2 subunit vaccine
US20240156935A1 (en) 2021-03-31 2024-05-16 Vib Vzw Vaccine Compositions for Trypanosomatids
WO2023046898A1 (en) 2021-09-23 2023-03-30 Viravaxx AG Hbv vaccine inducing pres-specific neutralizing antibodies
US20250082745A1 (en) 2021-12-13 2025-03-13 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Bacteriophage lambda-vaccine system
US20230190920A1 (en) 2021-12-19 2023-06-22 Massachusetts Institute Of Technology Compositions and methods for long-lasting germinal center responses to a priming immunization
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
WO2024133160A1 (en) 2022-12-19 2024-06-27 Glaxosmithkline Biologicals Sa Hepatitis b compositions
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54132218A (en) * 1978-04-01 1979-10-15 Toyo Soda Mfg Co Ltd Separation of saponin constituents
FR2456116A1 (fr) * 1979-05-11 1980-12-05 Sarget Lab Nouvelle saponine triterpenique derivee de la caulophyllogenine et ses applications therapeutiques
DE3040246C2 (de) * 1979-10-29 1985-01-10 Osaka Chemical Laboratory Co., Ltd., Osaka Sojasaponine A↓1↓ und A↓2↓ und ihre Verwendung
JPS617286A (ja) * 1984-06-22 1986-01-13 Kishimoto Sangyo Kk 単離サポニン製造方法

Also Published As

Publication number Publication date
JPH02504266A (ja) 1990-12-06
EP0362279A4 (en) 1990-05-14
EP0362279B2 (en) 1999-11-03
ATE116993T1 (de) 1995-01-15
WO1988009336A1 (en) 1988-12-01
DK175739B1 (da) 2005-02-07
CA1331443C (en) 1994-08-16
JP2731563B2 (ja) 1998-03-25
EP0362279A1 (en) 1990-04-11
AU1934088A (en) 1988-12-21
DE3852761T3 (de) 2000-06-21
EP0362279B1 (en) 1995-01-11
DE3852761T2 (de) 1995-09-07
DK602989A (da) 1989-11-29
AU616670B2 (en) 1991-11-07
DE3852761D1 (de) 1995-02-23

Similar Documents

Publication Publication Date Title
DK602989A (da) Saponinadjuvans
DK0606317T3 (da) Saponin-antigen-konjugater og anvendelsen deraf
GB2303855B (en) Helicobacter pylori antigenic protein preparation and immunoassays
UA40597C2 (uk) Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів
FI73995B (fi) Foerfarande foer framstaellning av farmakologiskt vaerdefulla 6,11-dihydro-dibenso-/b,e/-tiepin-11-n-alkyl- norskopinetrar.
PT1104306E (pt) Composicoes de cpg e adjuvantes de saponina e seus metodos
UA40596C2 (uk) Композиція вакцини та спосіб її одержання
SE7613851L (sv) Glukosaminderivat
ATE135918T1 (de) Verbesserte vakzinzusammensetzung
DK173883D0 (da) Substituerede 8-phenylxanthiner
MY125000A (en) Novel compositions
DE69112634D1 (de) Immunogene komplexe, insbesondere iscoms.
DK0482097T3 (da) Tensidpræparater og fremgangsmåder
PH17094A (en) D-homo steroids and pharmaceutical preparation thereof
ATE173936T1 (de) Impfstoffzusammensetzungen
AU2471201A (en) Plant lectins as mucosal adjuvants
IT8049346A0 (it) Composizione antigene relativo vaccino e procedimento di produzione
KR930703006A (ko) 백신, 특히 돼지의 흉막폐염 백신의 면역강화
IT8722486A0 (it) Uso del fattore di necrosi tumorale come adiuvante della risposta immunitaria.
WO1990015132A3 (en) Cloned treponema hyodysenteriae endoflagellar antigen
SU1672636A1 (ru) Адъювант для производства противоящурной вакцины
SE9702240D0 (sv) Vaccine compositions III

Legal Events

Date Code Title Description
PUP Patent expired